Neumora Therapeutics is trading at $0.81, up 17.07%, with no definitive catalyst identified for the September 22, 2026 move.
- No clear company-specific announcement explains the gain.
- Recent coverage highlighted NMRA-215 toxicology data, but did not explicitly link the intraday move to the news.
- Broader sentiment is mildly supportive, though limited major-index gains and speculative trading after recent declines may be contributing.